Amendment SA3-SR31

LRBa2575/1

PJD:cjs:rs

2003 - 2004 LEGISLATURE

SENATE AMENDMENT 3, TO 2003 SENATE RESOLUTION 31

March 9, 2004 - Offered by Senators Robson, Moore, Hansen, M. Meyer, Erpenbach, Plale, Risser, Decker, Chvala, Wirch, Lassa, Coggs and Carpenter.

SR31-SA3,1,1 At the locations indicated, amend the resolution as follows:

SR31-SA3,1,2 1. Page 2, line 13: after that line insert:

SR31-SA3,1,5 "Whereas, pharmaceutical companies' after-tax profits, after expenditures for research and development, averaged 17 percent from 1994 to 1998, compared with 5 percent for all other industries; and

SR31-SA3,1,7 Whereas, pharmaceutical companies spent $15.7 billion in 2000 on product promotion despite being protected from competition by current law; and

SR31-SA3,1,10 Whereas, pharmaceutical companies from 1993 to 1996 paid an average effective tax rate of 16.2 percent, compared to all other major industries, which paid an average effective tax rate of 27.3 percent; and".

SR31-SA3,1,11 (End)